Physician profile
Amanda Ehrgood-Perry
NPI 1801100987
$6,498.07
in general payments reported to CMS, 2019-2025
28 companies · $943 in 2025
The $943 reported for 2025 was more than what 90% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $702 · 2020: $578 · 2021: $649 · 2022: $2,837 · 2023: $327 · 2024: $462 · 2025: $943.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,732.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,731.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Vision Care, INC. | $2,294.15 | 2019-2025 | |
| Alcon Vision LLC | $1,461.88 | 2019-2025 | Dailies Total1, Precision7, Precision 1 |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $320.91 | 2019-2020 | |
| Oyster Point Pharma, INC. | $262.09 | 2022-2025 | Tyrvaya |
| Bausch & Lomb Americas INC. | $233.54 | 2022-2025 | Infuse, Xiidra, Miebo |
| Coopervision INC. | $206.22 | 2019-2025 | Myday Contact Lens |
| Novartis Pharmaceuticals Corporation | $193.35 | 2019-2023 | |
| Abbvie INC. | $164.69 | 2022-2023 | |
| Tarsus Pharmaceuticals, INC. | $158.11 | 2024-2025 | Xdemvy |
| Eyevance Pharmaceuticals LLC | $155.41 | 2020-2021 | |
| Rxsight INC | $141.75 | 2025 | Rxsight Contact Lens, Rxsight Injector Cartridge, Light Adjustable Lens (Lal) |
| Dompe US, INC. | $131.28 | 2022-2025 | Oxervate |
| Sun Pharmaceutical Industries INC. | $122.53 | 2019-2025 | |
| Glaukos Corporation | $112.15 | 2025 | Idosetr |
| Harrow Eye, LLC | $98.43 | 2024-2025 | Vevye |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $81.63 | 2021 | |
| Aerie Pharmaceuticals, INC. | $71.02 | 2019-2021 | |
| Apellis Pharmaceuticals, INC. | $59.24 | 2023-2025 | Syfovre |
| Shire North American Group INC | $39.64 | 2019 | |
| Sandoz INC. | $33.29 | 2024 | Cimerli |
| Genentech USA, INC. | $28.07 | 2024 | Vabysmo |
| Visioneering Technologies, INC. | $23.68 | 2019 | |
| Amgen INC. | $21.20 | 2024 | Tepezza |
| Ani Pharmaceuticals, INC. | $20.61 | 2024 | Purified Cortrophin Gel |
| Rayner Intraocular Lenses Limited | $17.17 | 2022 | |
| Sight Sciences, INC. | $16.35 | 2023 | Sion Surgical Instrument, Omni Surgical System |
| Regeneron Healthcare Solutions, INC. | $15.27 | 2019 | |
| Abb Con-Cise Optical Group LLC | $14.41 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Ehrgood-Perry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.